Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on February 19, 2007

Circulation. 2007
Published online before print February 19, 2007, doi: 10.1161/CIRCULATIONAHA.106.681718
A more recent version of this article appeared on March 13, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
115/10/1260    most recent
CIRCULATIONAHA.106.681718v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Said, S. I.
Right arrow Articles by Kort, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Said, S. I.
Right arrow Articles by Kort, S.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Pulmonary Hypertension
Related Collections
Right arrow Clinical genetics
Right arrow Animal models of human disease
Right arrow Smooth muscle proliferation and differentiation
Right arrow Pulmonary circulation and disease
Right arrow Other Vascular biology

Submitted on December 1, 2006
Accepted on January 2, 2007

Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide Gene

Sami I. Said MD*, Sayyed A. Hamidi MD, Kathleen G. Dickman PhD, Anthony M. Szema MD, Sergey Lyubsky MD, Richard Z. Lin MD, Ya-Ping Jiang MD, John J. Chen PhD, James A. Waschek PhD, and Smadar Kort MD

From the Departments of Medicine (S.I.S., S.A.H., K.G.D., A.M.S., R.Z.L., Y.-P.J., S.K.), Pathology (S.L.), and Preventive Medicine (J.J.C.), State University of New York at Stony Brook; Department of Veterans Affairs Medical Center, Northport, NY (S.I.S., S.A.H., K.G.D., A.M.S., S.L., R.Z.L.); and Department of Psychiatry, University of California, Los Angeles, Los Angeles (J.A.W.).

* To whom correspondence should be addressed. E-mail: sami.i.said{at}stonybrook.edu.

Background--Vasoactive intestinal peptide (VIP), a pulmonary vasodilator and inhibitor of vascular smooth muscle proliferation, has been reported absent in pulmonary arteries from patients with idiopathic pulmonary arterial hypertension (PAH). We have tested the hypothesis that targeted deletion of the VIP gene may lead to PAH with pulmonary vascular remodeling.

Methods and Results--We examined VIP knockout (VIP-/-) mice for evidence of PAH, right ventricular (RV) hypertrophy, and pulmonary vascular remodeling. Relative to wild-type control mice, VIP-/- mice showed moderate RV hypertension, RV hypertrophy confirmed by increased ratio of RV to left ventricle plus septum weight, and enlarged, thickened pulmonary artery and smaller branches with increased muscularization and narrowed lumen. Lung sections also showed perivascular inflammatory cell infiltrates. No systemic hypertension and no arterial hypoxemia existed to explain the PAH. The condition was associated with increased mortality. Both the vascular remodeling and RV remodeling were attenuated after a 4-week treatment with VIP.

Conclusions--Deletion of the VIP gene leads to spontaneous expression of moderately severe PAH in mice during air breathing. Although not an exact model of idiopathic PAH, the VIP-/- mouse should be useful for studying molecular mechanisms of PAH and evaluating potential therapeutic agents. VIP replacement therapy holds promise for the treatment of PAH, and mutations of the VIP gene may be a factor in the pathogenesis of idiopathic PAH.


Key words: cardiovascular diseases • genetics • hypertension, pulmonary • pathology • peptides • remodeling • vasculature




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. R. Stenmark, B. Meyrick, N. Galie, W. J. Mooi, and I. F. McMurtry
Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure
Am J Physiol Lung Cell Mol Physiol, December 1, 2009; 297(6): L1013 - L1032.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
E. C. Dempsey, M. J. Wick, V. Karoor, E. J. Barr, D. W. Tallman, C. A. Wehling, S. J. Walchak, S. Laudi, M. Le, M. Oka, et al.
Neprilysin Null Mice Develop Exaggerated Pulmonary Vascular Remodeling in Response to Chronic Hypoxia
Am. J. Pathol., March 1, 2009; 174(3): 782 - 796.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
H. H. Leuchte, C. Baezner, R. A. Baumgartner, D. Bevec, G. Bacher, C. Neurohr, and J. Behr
Inhalation of vasoactive intestinal peptide in pulmonary hypertension
Eur. Respir. J., November 1, 2008; 32(5): 1289 - 1294.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. Shifren, A. G. Durmowicz, R. H. Knutsen, G. Faury, and R. P. Mecham
Elastin insufficiency predisposes to elevated pulmonary circulatory pressures through changes in elastic artery structure
J Appl Physiol, November 1, 2008; 105(5): 1610 - 1619.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Respir DisHome page
K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert
Review: Therapeutic advances in pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265.
[Abstract] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly
Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 188 - 196.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. Humbert
Update in Pulmonary Arterial Hypertension 2007
Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 574 - 579.
[Full Text] [PDF]


Home page
JEMHome page
E. Daley, C. Emson, C. Guignabert, R. de Waal Malefyt, J. Louten, V. P. Kurup, C. Hogaboam, L. Taraseviciene-Stewart, N. F. Voelkel, M. Rabinovitch, et al.
Pulmonary arterial remodeling induced by a Th2 immune response
J. Exp. Med., February 18, 2008; 205(2): 361 - 372.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. A. Hamidi, S. Prabhakar, and S. I. Said
Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion
Eur. Respir. J., January 1, 2008; 31(1): 135 - 139.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Xu, O. Platoshyn, A. Makino, W. H. Dillmann, K. Akassoglou, C. V. Remillard, and J. X.-J. Yuan
Characterization of agonist-induced vasoconstriction in mouse pulmonary artery
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H220 - H228.
[Abstract] [Full Text] [PDF]